LPA
Sandeep Grover The LPA gene produces a serine proteinase, which functions to suppress the activity of tissue-type plasminogen activator I.
This protein is a significant component of lipoprotein(a) and undergoes proteolytic cleavage, generating fragments that adhere to atherosclerotic plaques and encourage the formation of blood clots. Elevated concentrations of this protein in the bloodstream are associated with an increased risk of atherosclerosis.
| rsID Number | Major Allele | Minor Allele | Minor Allele Frequency (%) | Major Amino Acid | Minor Amino Acid |
|---|---|---|---|---|---|
| rs12678919 | t | c | 5 | Ile | Met |
Discuss this information with your doctor before taking any course of action.
| rsID Number | Major Allele | Minor Allele | Minor Allele Frequency (%) |
|---|---|---|---|
| rs10455872 | a | g | 4 |
Risk Description
A specific genetic variant known in the LPA gene known as rs10455872 has been linked to elevated Lp(a) lipoprotein levels and an increased susceptibility to Coronary Heart Disease. 1
Individuals with the GG genotype face a 2.57-fold higher risk of developing coronary artery disease, while those with the AG genotype have a 1.51 times greater risk of experiencing coronary artery disease.
This genetic variant directly connects to both higher Lp(a) levels and an increased likelihood of developing coronary heart disease.
Discuss this information with your doctor before taking any course of action.
| rsID Number | Major Allele | Minor Allele | Minor Allele Frequency (%) | Major Amino Acid | Minor Amino Acid |
|---|---|---|---|---|---|
| rs3798220 | t | c | 1.6 | Ile | Met |
Risk Description
LPA variant for rs3798220 represents a genetic variation (SNP) located within the apolipoprotein(A) LPA gene.
This SNP has been linked to elevated levels of lipoprotein(a) in the bloodstream and an increased likelihood of experiencing cardiovascular issues, specifically coronary artery disease.
A study by Chasman et al., showed that individuals:
- with one copy of the minor allele C (heterozygous) exhibit a median Lp(a) level eight times higher,
- while those with two copies of the minor allele C (homozygous) exhibit a median Lp(a) level 15 times higher compared to individuals lacking the minor allele C.
The study further showed that C-allele carriers have two-fold higher risk of major cardiovascular events than non-carriers (age-adjusted hazard ratio (HR) = 2.21, 95% CI 1.39−3.52).
Individuals who carry the C-allele experience a reduced likelihood of cardiovascular events when they receive Aspirin treatment.
Lifestyle Considerations:
| Behavior | Description |
|---|---|
| Low dose aspirin |
*Consult a physician prior to taking low dose aspirin as a cardiovascular intervention.* Carriers of the “C” allele for rs3798220 could benefit from taking Aspirin as a preventive measure to reduce the risk of cardiac events, according to the ASPREE Trial and Women’s Health Study. The mechanism involves the increased clot risk that people with elevated Lp(a) tend to see. Since Lp(a) increases risk of clot formation but comes with an associated decreased risk of bleeding, one of the major side effects of concern for those taking aspirin as a preventative is mitigated. See our blog post summarizing both studies, here. |
Discuss this information with your doctor before taking any course of action.